MedTrace Logo

Impact of Virtual Reality on the Mental Health of Patients Undergoing Adjuvant Treatment for Colorectal Cancer

NCT05365256 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 98

Last updated 2022-05-12

No results posted yet for this study

Summary

The increase in the survival of cancer patients and the incidence of cancers leads to a rapid increase in the number of people living after a diagnosis of cancer.

Occupation during chemotherapy treatment time has been identified as an excellent way to support cancer patients. Studies show that distraction interventions increase tolerance to treatment, by decreasing the importance given to negative stimuli associated with chemotherapy and increasing pleasurable emotions.

In this context, virtual reality (VR) is a promising intervention for patients receiving chemotherapy. VR is considered a powerful painkiller, even more effective than other distractors, such as movies or video games for example.

Several studies have shown short-term beneficial effects of integrating VR in patients undergoing chemotherapy. This intervention would help patients better adhere to and tolerate treatment. Considering that positive emotions could be one of the underlying processes necessary for the effectiveness of VR, it would be possible to support the cancer patient towards better overall well-being thanks to these new technologies.

Investigators can therefore ask themselves the question of the impact that VR used during chemotherapy can have on the adaptation of patients to the disease and its treatments as well as on their psychological distress in the medium and long term.

Conditions

  • Cancer of Colon
  • Virtual Reality

Interventions

BEHAVIORAL

Standard distraction during chemotherapy treatment period

habitual distraction of patients during chemotherapy sessions authorized as part of routine care

BEHAVIORAL

Virtual distraction during chemotherapy treatment period

A virtual reality headset will be worn for 15 minutes per hour of treatment

Sponsors & Collaborators

  • GCS Ramsay Santé pour l'Enseignement et la Recherche

    collaborator OTHER

  • Ramsay Générale de Santé

    lead OTHER

Principal Investigators

  • Sophie Lantheaume, Dr · Ramsay Santé - Hôpital Privé Drôme

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-15
Primary Completion
2025-04-30
Completion
2025-04-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05365256 on ClinicalTrials.gov